[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657163":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":27,"studyPopulation":28,"armGroups":29,"interventions":35,"overallOfficials":23,"centralContacts":40,"locations":23,"responsibleParty":51,"collaborators":23,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":23,"enrollmentInfo":63,"targetDuration":23,"studyType":66,"phases":23,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":82,"whyStopped":23,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":23},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"Number of Predictive Multimodal Biomarkers identified","Discovery and validation of molecular, cellular, and imaging biomarkers associated with response or resistance to therapies, evaluated on progression-free survival.","Up to 10 years",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"Overall Survival Analysis by Biomarker Subgroup","Evaluation of overall survival based on biomarker-defined subgroups.",{"measure":18,"description":19,"timeFrame":12},"Multimodal biomarker performance","Assessment of the added value of combining multiple types of biomarkers (e.g., genomic + imaging).",{"measure":21,"description":22,"timeFrame":12},"Drug Sensitivity in PDO Models","Ex vivo response of PDOs to approved or experimental therapies, correlated with clinical outcomes.",null,{"allocation":23,"interventionModel":23,"interventionModelDescription":23,"primaryPurpose":23,"observationalModel":25,"timePerspective":26,"maskingInfo":23},"COHORT","PROSPECTIVE","Senocohort is a prospective, bicentric cohort study designed to collect clinico-biological data and establish a biobank of patient-derived tumor organoids (PDOs) from residual tissue samples obtained during routine care. The aim is to identify new multimodal biomarkers (molecular, cellular, and imaging) predictive of response or resistance to breast cancer therapies, with evaluation based on progression-free survival. The study targets an enriched population of hormone receptor-negative breast cancers, particularly triple-negative subtypes, which currently lack effective targeted treatments. Samples will be used for genomic analyses, PDO development, and circulating biomarker studies, with 10 years of clinical follow-up.","Patients aged 18 or older with a histologically confirmed diagnosis of breast cancer, treated at the Saint-Louis Hospital senology and breast surgery departments. Emphasis will be placed on hormone receptor-negative subtypes.",[30],{"label":31,"type":23,"description":32,"interventionNames":33},"Breast Cancer Patients at Saint-Louis Hospital","Patients with newly diagnosed or recurrent breast cancer managed at the breast surgery and senology units. Residual tumor tissue, blood, and clinical data will be collected for analysis.",[34],"Other: Patients follow-up",[36],{"type":6,"name":37,"description":38,"armGroupLabels":39,"otherNames":23},"Patients follow-up","Blood sampling, residual tissue material collection and clinical data collection",[31],[41,47],{"name":42,"role":43,"phone":44,"phoneExt":45,"email":46},"Luis Texeira, MD PhD","CONTACT","01 42 49 96 13","+33","luis.teixeira@aphp.fr",{"name":48,"role":43,"phone":49,"phoneExt":45,"email":50},"Jérôme Lambert, MD PhD","0142499742","jerome.lambert@u-paris.fr",{"type":52,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100657163","senocohort-identification-of-predictive-biomarkers-in-breast-cancer-treatment-100657163",false,"NCT07833891","Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment","Recherche de Biomarqueurs prédictifs de réponse ou de résistance Dans Les Traitements Des Cancers du Sein","SENOCOHORT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed breast cancer\n* Managed at Saint-Louis Hospital\n* No opposition to participation in research\n* Affiliation to the French national health system\n\nExclusion Criteria:\n\n* Expressed opposition to research\n* Legal incapacity or under legal protection\n* Patients under State Medical Aid (AME)","ALL","18 Years",{"count":64,"type":65},500,"ESTIMATED","OBSERVATIONAL","Breast cancer is a heterogeneous disease with multiple molecular subtypes, each requiring tailored therapeutic strategies. The recent introduction of targeted therapies, immunotherapies, and antibody-drug conjugates has expanded treatment options, yet their efficacy varies depending on tumor subtype. This non-interventional study aims to identify novel predictive biomarkers of response or resistance to these emerging therapies. The Senocohort study will prospectively collect clinical, biological, imaging, and organoid-derived data from breast cancer patients, with a focus on hormone receptor-negative tumors. The ultimate goal is to improve precision medicine strategies and patient stratification",[69,70],"Breast Cancer","Breast Cancer (Triple Negative Type)",[72,73,74,75,76,77,78,79,80,81],"hormone receptor-negative breast cancer","Breast neoplasms","Biomarkers","Precision medicine","Tumor organoids","Predictive biomarkers","Triple-Negative Breast Neoplasms","Circulating DNA","Patient-Derived Organoid","Immunotherapy","NOT_YET_RECRUITING","2026-09-16",{"date":85,"type":86},"2026-09-22","ACTUAL",{"date":88,"type":65},"2026-10-01",{"date":90,"type":65},"2041-10-01",{"name":5,"class":6}]